VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on VolitionRX. The associated price target is $1.00.

Yi Chen has given his Buy rating due to a combination of factors, including VolitionRx’s solid topline expansion and emerging commercial traction despite near-term losses. The company delivered 40% year-over-year revenue growth in 2025 and is actively engaging with multiple leading diagnostic and liquid biopsy players, which could translate into additional licensing agreements and stronger revenue momentum in 2026.

Chen also highlights the compelling early data from the company’s Capture-Seq liquid biopsy technology, which showed very high sensitivity and specificity for early-stage cancers and could support future applications in multi-cancer early detection and minimal residual disease monitoring. While acknowledging the need for additional capital beyond mid-2026, he views the technology platform, potential partnering upside, and revenue growth prospects as outweighing financing risks, justifying a Buy rating even as the 12-month price target is reduced to $1 primarily due to share dilution.

Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, Alpha Tau Medical Ltd, and Opko Health. According to TipRanks, Chen has an average return of -1.5% and a 38.26% success rate on recommended stocks.

In another report released today, JonesTrading also reiterated a Buy rating on the stock with a $3.00 price target.